Today: 9 June 2026
Browse Category

DFM:DFM 21 February 2026 - 28 February 2026

Stock Market Today

  • Redwire Shares Fall After $500 Million At-The-Market Stock Offering Announcement
    June 9, 2026, 10:33 AM EDT. Redwire Corp shares dropped 6.5% after the company filed a $500 million at-the-market (ATM) stock program with the U.S. SEC. The ATM program allows Redwire to sell shares gradually at prevailing prices, providing flexible capital raising but risking shareholder dilution. The stock slide comes despite strong underlying demand, with CEO Peter Cannito citing a $498 million backlog and a 57.9% revenue jump in Q1. Redwire's $3.37 billion market cap contrasts with its ongoing net losses, and CEO reaffirmed 2026 revenue guidance of $450-$500 million. The stock decline was specific to Redwire following its financing news, while other space sector peers advanced.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop